MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Dual-task interference on weight-shifting in Parkinson’s Disease with freezing of gait and without freezing of gait

    YT. Hung, CY. Tsai, RM. Wu, CY. Huang (Taipei, Taiwan)

    Objective: To investigate the control of dual-task weight-shifting in Parkinson's disease (PD) with freezing of gait (FOG) and without FOG). Background: With more impairment in…
  • MDS Virtual Congress 2021

    Cuneiform Nucleus Deep Brain Stimulation for Freezing of Gait in Parkinson’s disease. Initial clinical report.

    C. Luca, S. Chang, I. Cajigas, J. Guest, I. Haq, B. Noga, J. Jagid (Miami, USA)

    Objective: Here we report a first in human targeting of Cuneiform Nucleus (CnF) using MR tractography, observation of intraoperative stimulation patterns and stimulation precision benefits of…
  • MDS Virtual Congress 2021

    A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.

    SH. Pasternak, C. Silviera, K. Coleman, E. Finger, J. Wells, M. Borrie, S. Morrow, G. Zou, R. Bartha, P. Macdonald, ME. Jenkins, M. Jog, R. Tirona, CA. Rupar (London, Canada)

    Objective: Currently there are no disease-treatments for Synucleinopathies including Parkinson’s disease dementia (PDD). Our objective is to use Ambroxol to target GBA/Glucocerebrosidase to treat PDD.…
  • MDS Virtual Congress 2021

    Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease

    J. Suescun, M. Schiess, Z. Jiang, V. Thyne, T. Iqbal, N. Utay, M. Newmark, A. Dupont, A. Alexander, H. Dupont (Houston, USA)

    Objective: To evaluate the impact of fecal microbiome transplant (FMT) on disease progression as a secondary outcome of a safety study using PRIM-DJ2727 in Parkinson's…
  • MDS Virtual Congress 2021

    The effect of medical xenon on patients with advanced stages of the Parkinson’s disease with motor fluctuations

    R. Bogdanov, E. Vasilchenko, A. Dobrovolsky, P. Ratmanova, D. Napalkov, V. Bogin (Moscow, Russian Federation)

    Objective: The aim of the study to increase the effectiveness of pharmacotherapy in patients with advanced stages of Parkinson's disease (PD) with motor fluctuations, using…
  • MDS Virtual Congress 2021

    Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool

    A. Fasano, V. Fung, K. Seppi, Z. Pirtosek, L. Bergmann, A. Alobaidi, K. Onuk (Toronto, Canada)

    Objective: This post-hoc analysis evaluated uncontrolled patients from OBSERVE-PD identified as advanced Parkinson’s disease (APD) based on domains evaluated in section 2 of the MANAGE-PD…
  • MDS Virtual Congress 2021

    IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW

    C. Kalva-Filho, M. Kuroda, E. Costa, J. Corradini, F. Barbieri (Bauru, Brazil)

    Objective: To explore the current evidence and identify knowledge gaps, we conducted a scoping review about the hypoxia exposure effects on people with Parkinson’s disease…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data

    M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco (San Sebastián Reyes, Spain)

    Objective: To evaluate the efficacy and tolerability of opicapone in patients in Parkinson’s disease (PD) patients with early/simple motor fluctuations (E/S-MF) in the Spanish clinical…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

    A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

    Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…
  • MDS Virtual Congress 2021

    The gender gap in Parkinson’s disease before and after Subthalamic Nucleus Deep Brain Stimulation surgery: preliminary results of a retrospective study.

    A. Trinchillo, F. Vitulli, T. Somma, F. Esposito (Naples, Italy)

    Objective: Gender differences in several neurodegenerative disorders have been extensively investigated. Nowadays, evidence and interest about sex-related distinctions regarding Parkinson's disease (PD) are increasing. The aim…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley